None listed
Conditions
Interventions
None listed
Sponsors
Keimyung University Dongsan Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) A patient with glaucoma who is 19 years of age or older and has been instilling one or more antiglaucoma eye drops bilaterally for at least one, 2) Based on the Korean dry eye treatment guidelines at the time of first enrolling, and the diagnostic criteria presented by the Dry Eye Workshop in 2007, dry eye syndrome of level 2 or higher 3) Patients who can be followed up for at least 4 months 4) Patients who accurately understands the details of the clinical trial and has written a consent form from a voluntary doctor
Exclusion criteria
Exclusion criteria: 1) Level 1 and 2 mild dry eye syndrome patients 2) Those who have had hypersensitivity reactions to this drug or other drugs, or those with a history of clinically significant hypersensitivity reactions 3) Patients who are pregnant, lactating, or planning to become pregnant 4) Those who participated in other clinical trials within 3 months before the first administration date 5) If there is a history of corneal or glaucoma surgery or intraocular surgery within 6 months of screening 6) Patients who want to wear contact lenses during the clinical trial period 7) Patients with eye diseases that require treatment other than dry eye syndrome and glaucoma 8) Patients received lacrimal punctal surgery (punctal plug and surgical lacrimal closure) within 1 month before instillation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ocular surface disease index;Tear break up time;Ocular surface score | — |
Secondary
| Measure | Time frame |
|---|---|
| Best corrected visual acuity;intraocular pressure;tear meniscus height;Matrix metalloproteinase-9;tear osmolality;Schirmer's test;Visual field test | — |
Countries
Korea, Republic of
Contacts
Public ContactJong Hwa Jun
Keimyung University Dongsan Hospital
Outcome results
None listed